Latest Synchron news, funding rounds and robotics & AI coverage. 2 articles tracked by The Robotics Media.
Synchron is a New York- and Brooklyn-based brain-computer interface company whose Stentrode implant is threaded through a blood vessel and lodged against the motor cortex, recording neural signals from inside the vasculature. The endovascular design avoids the craniotomy required by Neuralink's N1, trading electrode count for a procedure based on routine catheter techniques.
The company holds the first investigational device exemption granted to a chronically implanted BCI in the United States and won an FDA Breakthrough Device designation in August 2020. Its COMMAND study met its primary safety endpoint across all six patients in September 2024, paving the way for a 2026 pivotal trial. Synchron has integrated with Apple's BCI HID input standard, partners with NVIDIA on edge decoding via Holoscan and unveiled its Chiral brain foundation model at GTC 2025.